ProMIS Neurosciences (PMN) director granted options on 16,500 shares

Rhea-AI Filing Summary

ProMIS Neurosciences Inc. director Eugene Williams reported receiving two option grants to buy common shares. On May 20, 2026, he was awarded options for 11,000 shares and 5,500 shares, each with an exercise price of $10.77 per share and expiring on May 20, 2036.

According to the footnotes, the 11,000-share option vests in full on May 20, 2027, subject to his continued service on the board. For the 5,500-share option, 25% vested upon grant and the remaining shares vest ratably over 36 months, also conditioned on continued board service. These are compensation-related awards, not open‑market purchases.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Williams Eugene

Role null

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy)	5,500	$0.00	--
Grant/Award	Option (right to buy)	11,000	$0.00	--

Holdings After Transaction: Option (right to buy) — 5,500 shares (Direct, null)

Footnotes (1)

1. The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board. 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.

Key Figures

Option grant size: 11,000 options Additional option grant size: 5,500 options Exercise price: $10.77 per share +1 more

4 metrics

Option grant size 11,000 options Director grant dated May 20, 2026

Additional option grant size 5,500 options Second director grant dated May 20, 2026

Exercise price $10.77 per share Applies to both option grants

Option expiration May 20, 2036 Expiration date for both grants

Key Terms

Option (right to buy), grant/award acquisition, vest in full, vesting ratably over thirty-six months

4 terms

Option (right to buy) financial

"security_title: "Option (right to buy)""

grant/award acquisition financial

"transaction_action: "grant/award acquisition""

vest in full financial

"The shares subject to this option shall vest in full on May 20, 2027"

vesting ratably over thirty-six months financial

"remaining shares vesting ratably over thirty-six months, subject to continued service"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Williams Eugene

(Last) (First) (Middle)

C/O PROMIS NEUROSCIENCES INC.

SUITE 200, 1920 YONGE STREET

(Street)

TORONTO M4S 3E2

(City) (State) (Zip)

ONTARIO, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
ProMIS Neurosciences Inc. [ PMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	$10.77	05/20/2026		A		5,500		(1)	05/20/2036	Common Shares	5,500	$0	5,500	D
Option (right to buy)	$10.77	05/20/2026		A		11,000		(2)	05/20/2036	Common Shares	11,000	$0	11,000	D

Explanation of Responses:

1. The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board.

2. 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.

	/s/ Max A. Milbury, Attorney in Fact for Eugene Williams	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did ProMIS Neurosciences (PMN) report for Eugene Williams?

ProMIS Neurosciences reported that director Eugene Williams received two stock option grants. He was awarded options over 11,000 and 5,500 common shares, both dated May 20, 2026, as part of his board compensation rather than open‑market share purchases.

How many ProMIS Neurosciences (PMN) options did Eugene Williams receive?

Eugene Williams received options covering a total of 16,500 common shares in ProMIS Neurosciences. One grant is for 11,000 shares and another for 5,500 shares, providing the right to buy shares at a preset exercise price if vesting conditions are met.

What is the exercise price of Eugene Williams’s ProMIS (PMN) stock options?

Both of Eugene Williams’s option grants carry an exercise price of $10.77 per share. This is the fixed price at which he can buy ProMIS Neurosciences common shares once the options vest and before they expire on May 20, 2036.

When do Eugene Williams’s ProMIS Neurosciences (PMN) options vest?

The 11,000-share option vests in full on May 20, 2027, if he continues serving on the board. For the 5,500-share option, 25% vested at grant and the remaining shares vest monthly over 36 months, also contingent on continued board service.

Are Eugene Williams’s ProMIS (PMN) option grants open‑market share purchases?

No, these are not open‑market purchases. The Form 4 shows option grants classified as compensation awards, giving Eugene Williams the right to buy ProMIS Neurosciences shares at $10.77, subject to vesting, rather than immediate share acquisitions in the market.